GoodRx Holdings, Inc. (GDRX) Current Ratio
- Current ratio · latest quarter: Value 1.38×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.38× | Current assets / current liabilities. $1.60B ÷ $1.16B ≈ 1.38× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.60B USD | Assets, Current |
| Current obligations | 1.16B USD | Liabilities, Current |
| Cash and equivalents | 296.11M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 182.14M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 8.91M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 5.00M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.60B | $1.16B | $296.11M | (m) | $182.14M | (m) | $8.91M | $5.00M | 1.38× |
| 2026-03-31 | $1.27B | $859.20M | $235.71M | (m) | $232.72M | (m) | $14.53M | $5.00M | 1.47× |
| 2025-12-31 | $643.10M | $246.00M | $261.82M | (m) | $235.75M | (m) | $19.41M | $5.00M | 2.61× |
| 2025-09-30 | $565.51M | $181.86M | $273.53M | (m) | $203.74M | (m) | $28.73M | $5.00M | 3.11× |
| 2025-06-30 | $550.61M | $130.91M | $281.32M | (m) | $189.03M | (m) | $25.41M | $5.00M | 4.21× |
| 2025-03-31 | $540.21M | $103.38M | $300.98M | (m) | $160.12M | (m) | $15.26M | $5.00M | 5.23× |
| 2024-12-31 | $659.25M | $123.90M | $448.35M | (m) | $145.93M | (m) | $14.14M | $5.00M | 5.32× |
| 2024-09-30 | $626.80M | $114.36M | $423.78M | (m) | $130.80M | (m) | $12.39M | $3.75M | 5.48× |
| 2024-06-30 | $750.55M | $102.47M | $524.90M | (m) | $161.77M | (m) | $16.88M | $7.03M | 7.32× |
| 2024-03-31 | $732.80M | $116.52M | $533.29M | (m) | $144.77M | (m) | $33.52M | $7.03M | 6.29× |
| 2023-12-31 | $872.79M | $122.56M | $672.30M | (m) | $143.61M | (m) | $36.27M | $8.79M | 7.12× |
| 2023-09-30 | $969.10M | $117.82M | $794.90M | (m) | $121.15M | (m) | $32.91M | $7.03M | 8.23× |
| 2023-06-30 | $919.25M | $82.55M | $761.99M | (m) | $123.38M | (m) | $6.79M | $7.03M | 11.14× |
| 2023-03-31 | $907.02M | $68.98M | $761.08M | (m) | $116.44M | (m) | $12.39M | $7.03M | 13.15× |
| 2022-12-31 | $919.69M | $76.32M | $757.16M | (m) | $117.14M | (m) | $17.70M | $7.03M | 12.05× |
| 2022-09-30 | $878.39M | $84.97M | $728.79M | (m) | $120.89M | (m) | $10.86M | $7.03M | 10.34× |
| 2022-06-30 | $893.96M | $79.62M | $730.54M | (m) | $122.88M | (m) | $16.82M | $7.03M | 11.23× |
| 2022-03-31 | $994.72M | $59.36M | $845.43M | (m) | $123.28M | (m) | $12.82M | $7.03M | 16.76× |
| 2021-12-31 | $1.09B | $81.11M | $941.11M | (m) | $118.08M | (m) | $17.50M | $7.03M | 13.42× |
| 2021-09-30 | $1.05B | $72.68M | $912.02M | (m) | $98.51M | (m) | $17.28M | $7.03M | 14.47× |
| 2021-06-30 | $1.08B | $65.49M | $894.70M | (m) | $87.00M | (m) | $18.38M | $7.03M | 16.43× |
| 2021-03-31 | $1.12B | $63.05M | $990.46M | (m) | $74.40M | (m) | $15.10M | $7.03M | 17.82× |
| 2020-12-31 | $1.09B | $59.55M | $968.69M | (m) | $68.73M | (m) | $10.29M | $7.03M | 18.24× |
| 2020-09-30 | $1.18B | $60.16M | $1.08B | (m) | $63.52M | (m) | $14.01M | $7.03M | 19.63× |
| 2019-12-31 | $86.58M | $33.37M | $26.05M | (m) | $48.13M | (m) | $7.85M | $7.03M | 2.59× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.